Impact of depression at early and late phases following acute coronary syndrome on long-term cardiac outcomes

2020 ◽  
Vol 260 ◽  
pp. 592-596 ◽  
Author(s):  
Jae-Min Kim ◽  
Robert Stewart ◽  
Ju-Wan Kim ◽  
Hee-Ju Kang ◽  
Sung-Wan Kim ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Coronary Syndrome ◽  
Cardiac Outcomes

scholarly journals Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study

2020 ◽  
pp. 1-11
Author(s):  
Jae-Min Kim ◽  
Robert Stewart ◽  
Hee-Ju Kang ◽  
Seon-Young Kim ◽  
Ju-Wan Kim ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Depressive Disorder ◽  
Randomised Clinical Trial ◽  
Diagnosis And Treatment ◽  
Depression Screening ◽  
Cardiac Events ◽  
Coronary Syndrome ◽  
Cardiac Outcomes ◽  
Appropriate Treatment

Abstract Background To investigate the impacts of depression screening, diagnosis and treatment on major adverse cardiac events (MACEs) in acute coronary syndrome (ACS). Methods Prospective cohort study including a nested 24-week randomised clinical trial for treating depression was performed with 5–12 years after the index ACS. A total of 1152 patients recently hospitalised with ACS were recruited from 2006 to 2012, and were divided by depression screening and diagnosis at baseline and 24-week treatment allocation into five groups: 651 screening negative (N), 55 screening positive but no depressive disorder (S), 149 depressive disorder randomised to escitalopram (E), 151 depressive disorder randomised to placebo (P) and 146 depressive disorder receiving medical treatment only (M). Results Cumulative MACE incidences over a median 8.4-year follow-up period were 29.6% in N, 43.6% in S, 40.9% in E, 53.6% in P and 59.6% in M. Compared to N, screening positive was associated with higher incidence of MACE [adjusted hazards ratio 2.15 (95% confidence interval 1.63–2.83)]. No differences were found between screening positive with and without a formal depressive disorder diagnosis. Of those screening positive, E was associated with a lower incidence of MACE than P and M. M had the worst outcomes even compared to P, despite significantly milder depressive symptoms at baseline. Conclusions Routine depression screening in patients with recent ACS and subsequent appropriate treatment of depression could improve long-term cardiac outcomes.

Impact of Suicidal Ideation on Long-Term Cardiac Outcomes in Patients with Acute Coronary Syndrome: Sex-Specific Differences

2018 ◽  
Vol 87 (5) ◽  
pp. 311-312 ◽  
Author(s):  
Jae-Min Kim ◽  
Robert Stewart ◽  
Hee-Joon Lee ◽  
Hee-Ju Kang ◽  
Kyung-Yeol Bae ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Suicidal Ideation ◽  
Coronary Syndrome ◽  
Cardiac Outcomes

scholarly journals Effect of Escitalopram vs Placebo Treatment for Depression on Long-term Cardiac Outcomes in Patients With Acute Coronary Syndrome

JAMA ◽  
2018 ◽  
Vol 320 (4) ◽  
pp. 350 ◽  
Author(s):  
Jae-Min Kim ◽  
Robert Stewart ◽  
Yong-Seong Lee ◽  
Hee-Joon Lee ◽  
Min Chul Kim ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Placebo Treatment ◽  
Coronary Syndrome ◽  
Cardiac Outcomes

scholarly journals Interaction between BDNF val66met polymorphism and personality on long-term cardiac outcomes in patients with acute coronary syndrome

PLoS ONE ◽  
2019 ◽  
Vol 14 (12) ◽  
pp. e0226802
Author(s):  
Jae-Min Kim ◽  
Robert Stewart ◽  
Seon-Young Kim ◽  
Ju-Wan Kim ◽  
Hee-Ju Kang ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Val66met Polymorphism ◽  
Coronary Syndrome ◽  
Cardiac Outcomes ◽  
Bdnf Val66met Polymorphism

Long Term Prognostic Utility of Matrix Metalloproteinase-9 in Patients with Acute Coronary Syndrome – A Systematic Review

2020 ◽  
Vol 21 ◽  
Author(s):  
Anamika Das ◽  
Melvin George ◽  
Durga Jha ◽  
Luxitaa Goenka
Keyword(s):  
Acute Coronary Syndrome ◽  
High Risk ◽  
Matrix Metalloproteinase ◽  
Developed Countries ◽  
Left Ventricular ◽  
Original Research ◽  
Coronary Syndrome ◽  
Potential Biomarker ◽  
Prognostic Utility

Background: Acute coronary syndrome (ACS) is the leading cause for morbidity and mortality in developed countries. Numerous groups have explored single and multiple biomarker strategies to identify diagnostic prognosticators of ACS which will improve our ability to identify high-risk individuals. Matrix metalloproteinase (MMP-9) is one potential biomarker which has been widely studied in ACS. Recent reports have showed the prognostic utility of MMP-9, but due to inconsistent results, it has not been possible to draw firm conclusions. Objective: This review aims to explore the ability of MMP-9 to predict long-term prognosis of ACS. To clarify this issue, we conducted a literature review to provide a comprehensive assessment of MMP-9 levels in ACS patients. Method: We retrieved a total of 1501 articles from PubMed and Google Scholar. After thorough scrutiny, 12 original research articles were found fulfilling the inclusion exclusion criteria. MMP-9’s ability as a biomarker of prognostication post ACS was reviewed. PRISMA guidelines were used for reporting. Result: The results revealed that MMP-9, apart from being an efficient diagnostic biomarker for ACS, helps in predicting the future risk of ACS with disease outcome. Positive correlation was found between plasma MMP-9 and left ventricular remodeling. A positive association was also found between cardiovascular death and higher MMP-9 levels. Conclusion: MMP-9 can be a potential prognostic marker for ACS and aid in identifying high risk patients for intensive management during follow -up.

Sign in / Sign up

Export Citation Format

Share Document